论文部分内容阅读
目的探讨C反应蛋白(CRP)与D-二聚体(D-D)在非霍奇金淋巴瘤和白血病中的表达情况,为临床病理研究和制定治疗方案提供依据。方法 32例非霍奇金淋巴瘤患者列入淋巴瘤组,30例白血病患者列入白血病组,同期体检结果为健康者30例列入对照组。3组受试者均于入院24h以内无菌抽取5ml静脉血液,装入试管并贴好标签,离心处理检测CRP和D-D含量。结果淋巴瘤组和白血病组患者CRP和D-D值均明显高于对照组,差异具有统计学意义(FCRP=6.87,FD-D=6.69,P﹤0.01);淋巴瘤组患者与白血病组患者CRP与D-D值差异无统计学意义(P﹥0.05)。淋巴瘤组患者和白血病组患者CRP和D-D阳性率明显高于对照组,差异有统计学意义(χ~2=8.59~12.56,P﹤0.01);淋巴瘤组与白血病组患者CRP与D-D比较,差异均无统计学意义(χ~2=0.26~2.05,P﹥0.05)。结论非霍奇金淋巴瘤和白血病患者血液中CRP和D-D含量明显高于健康者,临床对两种指标的检测对疾病检测、制定治疗方案、疗效观察以及预后等具有一定的辅助作用。
Objective To investigate the expression of C-reactive protein (CRP) and D-dimer (D-D) in non-Hodgkin’s lymphoma and leukemia, and to provide evidence for clinical and pathological research and treatment planning. Methods Thirty-two non-Hodgkin’s lymphoma patients were enrolled in the lymphoma group, 30 leukemia patients were enrolled in the leukemia group, and 30 healthy people were included in the control group in the same period. All the subjects were aseptically took 5 ml of venous blood within 24h after admission. The tubes were filled in tubes and labeled, and the contents of CRP and D-D were detected by centrifugation. Results The CRP and DD of patients with lymphoma and leukemia were significantly higher than those of the control group (FCRP = 6.87, FD-D = 6.69, P <0.01). CRP and DD in patients with lymphoma and leukemia DD value difference was not statistically significant (P> 0.05). The positive rates of CRP and DD in lymphoma group and leukemia group were significantly higher than those in control group (χ ~ 2 = 8.59-12.56, P <0.01). CRP and DD in lymphoma group and leukemia group were significantly higher than those in control group There was no significant difference (χ ~ 2 = 0.26 ~ 2.05, P> 0.05). Conclusions The blood levels of CRP and D-D in patients with non-Hodgkin’s lymphoma and leukemia are significantly higher than those in healthy people. The detection of these two indexes in clinic can help to detect the disease, make the treatment plan, observe the curative effect and prognosis.